Theratechnologies Inc. Asset Resilience Ratio
Theratechnologies Inc. asset resilience ratio. Theratechnologies Inc. (TH) has an Asset Resilience Ratio of 1.80% as of May 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TH days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Theratechnologies Inc. (1999–2024)
Asset resilience ratio of Theratechnologies Inc. from 1999 to 2024. This chart shows how Theratechnologies Inc.'s Asset Resilience Ratio has changed over time. Read Theratechnologies Inc. total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Theratechnologies Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TH current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$462.00K | 0.9% |
| Short-term Investments | CA$462.00K | 0.9% |
| Total Liquid Assets | CA$924.00K | 1.80% |
Asset Resilience Insights
- Limited Liquidity: Theratechnologies Inc. maintains only 1.80% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Theratechnologies Inc. Industry Peers by Asset Resilience Ratio
Compare Theratechnologies Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Theratechnologies Inc. Asset Resilience Ratio by Year (1999–2024)
Theratechnologies Inc. asset resilience ratio by year from 1999 to 2024. The table below shows the annual Asset Resilience Ratio data for Theratechnologies Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-11-30 | 13.96% | CA$7.45 Million ≈ $5.39 Million |
CA$53.34 Million ≈ $38.59 Million |
-2.22pp |
| 2023-11-30 | 16.18% | CA$12.58 Million ≈ $9.10 Million |
CA$77.77 Million ≈ $56.26 Million |
-3.58pp |
| 2022-11-30 | 19.76% | CA$18.43 Million ≈ $13.33 Million |
CA$93.26 Million ≈ $67.46 Million |
-13.72pp |
| 2021-11-30 | 33.48% | CA$39.91 Million ≈ $28.87 Million |
CA$119.21 Million ≈ $86.24 Million |
+17.44pp |
| 2020-11-30 | 16.04% | CA$16.06 Million ≈ $11.62 Million |
CA$100.14 Million ≈ $72.44 Million |
-4.32pp |
| 2019-11-30 | 20.35% | CA$23.93 Million ≈ $17.31 Million |
CA$117.56 Million ≈ $85.04 Million |
+2.92pp |
| 2018-11-30 | 17.43% | CA$19.39 Million ≈ $14.03 Million |
CA$111.25 Million ≈ $80.48 Million |
-38.28pp |
| 2017-11-30 | 55.71% | CA$33.03 Million ≈ $23.89 Million |
CA$59.29 Million ≈ $42.89 Million |
+43.17pp |
| 2016-11-30 | 12.54% | CA$4.95 Million ≈ $3.58 Million |
CA$39.43 Million ≈ $28.52 Million |
+4.93pp |
| 2014-11-30 | 7.61% | CA$2.17 Million ≈ $1.57 Million |
CA$28.51 Million ≈ $20.62 Million |
+7.21pp |
| 2013-11-30 | 0.40% | CA$93.25K ≈ $67.45K |
CA$23.40 Million ≈ $16.93 Million |
-0.01pp |
| 2012-11-30 | 0.41% | CA$150.00K ≈ $108.51K |
CA$36.58 Million ≈ $26.46 Million |
-1.01pp |
| 2011-11-30 | 1.42% | CA$728.26K ≈ $526.81K |
CA$51.20 Million ≈ $37.04 Million |
-1.17pp |
| 2010-11-30 | 2.60% | CA$1.82 Million ≈ $1.32 Million |
CA$70.28 Million ≈ $50.84 Million |
-11.85pp |
| 2009-11-30 | 14.44% | CA$9.49 Million ≈ $6.86 Million |
CA$65.70 Million ≈ $47.52 Million |
-5.79pp |
| 2008-11-30 | 20.23% | CA$8.82 Million ≈ $6.38 Million |
CA$43.60 Million ≈ $31.54 Million |
-16.59pp |
| 2007-11-30 | 36.82% | CA$27.45 Million ≈ $19.86 Million |
CA$74.55 Million ≈ $53.93 Million |
+1.46pp |
| 2006-11-30 | 35.36% | CA$15.79 Million ≈ $11.42 Million |
CA$44.65 Million ≈ $32.30 Million |
+12.03pp |
| 2005-11-30 | 23.33% | CA$10.72 Million ≈ $7.75 Million |
CA$45.93 Million ≈ $33.23 Million |
-2.44pp |
| 2004-11-30 | 25.77% | CA$14.75 Million ≈ $10.67 Million |
CA$57.23 Million ≈ $41.40 Million |
-15.78pp |
| 2003-11-30 | 41.55% | CA$30.28 Million ≈ $21.90 Million |
CA$72.88 Million ≈ $52.72 Million |
+13.72pp |
| 2002-11-30 | 27.83% | CA$24.98 Million ≈ $18.07 Million |
CA$89.78 Million ≈ $64.95 Million |
-6.75pp |
| 2001-11-30 | 34.58% | CA$31.25 Million ≈ $22.61 Million |
CA$90.38 Million ≈ $65.38 Million |
+2.10pp |
| 2000-11-30 | 32.48% | CA$17.86 Million ≈ $12.92 Million |
CA$54.99 Million ≈ $39.78 Million |
-48.33pp |
| 1999-11-30 | 80.81% | CA$14.87 Million ≈ $10.76 Million |
CA$18.40 Million ≈ $13.31 Million |
-- |
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatm… Read more